Premier Path Wealth Partners’s Idexx Laboratories IDXX Stock Holding History

Premier Path Wealth Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Sell	472 -82	-15%	-$46K	0.03%	378
2026 Q1	$311K	Buy	554 +42	+8%	+$26.9K	0.04%	340
2025 Q4	$346K	Buy	512 +72	+16%	+$49K	0.04%	307
2025 Q3	$281K	Buy	440 +43	+11%	+$26.1K	0.04%	341
2025 Q2	$213K	Buy	+397	New	+$190K	0.03%	373
2024 Q4	–	Sell	-530	Closed	-$268K	–	378
2024 Q3	$268K	Sell	530 -116	-18%	-$56.4K	0.04%	321
2024 Q2	$315K	Buy	646 +80	+14%	+$40.2K	0.05%	284
2024 Q1	$307K	Sell	566 -6	-1%	-$3.28K	0.06%	271
2023 Q4	$317K	Buy	+572	New	+$269K	0.07%	246

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Premier Path Wealth Partners's IDXX Position: Q2 2026 in Review

Premier Path Wealth Partners reduced its Idexx Laboratories (IDXX) stake by 15% in Q2 2026, selling an estimated $46K and leaving 472 shares worth $248K. The position accounts for 0.03% of the portfolio, ranked #378.

Premier Path Wealth Partners first reported a position in IDXX in Q4 2023 and has held it in 9 quarters since. The position peaked at $346K in Q4 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Premier Path Wealth Partners held 472 shares of Idexx Laboratories worth $248K as of Q2 2026.
Premier Path Wealth Partners sold 82 Idexx Laboratories shares in Q2 2026, an estimated $46K.
Idexx Laboratories made up 0.03% of Premier Path Wealth Partners's portfolio in Q2 2026, its #378 holding.
Premier Path Wealth Partners first reported a position in Idexx Laboratories in Q4 2023 and has held it in 9 quarters since.
Premier Path Wealth Partners's Idexx Laboratories position peaked at $346K in Q4 2025.
1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.